News Amgen's big reveal of obesity data falls a little flat Top-line phase 2 results with Amgen's MariTide drug for obesity are finally in, but don't seem to have lived up to investor expectations
News Amgen plays down safety concern with obesity candidate Amgen has rebuffed claims made by an analyst suggesting that its obesity drug MariTide is associated with reductions in bone mineral density that could undermine its ability to compete in t
Market Access Policy in focus: Trump’s Most Favoured Nations drug pricing ... Alice Valder Curran, a partner at Hogan Lovells, provides an update on what's happening right now with Most Favoured Nations drug pricing.
Sales & Marketing FH25: Individual centric investing with Steve Seuntjens In a new FH25 podcast episode, Deep Dive editor Eloise McLennan speaks with Steve Seuntjens, Partner at PHS Capital.